Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: Meta-analyses of data on 50 000 individuals

The Lancet

Volumn 381, Issue 9871, 2013, Pages 1029-1036

  Vollset, Stein Emil ^a   Clarke, Robert ^b   Lewington, Sarah ^b   Ebbing, Marta ^c   Halsey, Jim ^b   Lonn, Eva ^d   Armitage, Jane ^b   Manson, Joann E ^e   Hankey, Graeme J ^f   Spence, J David ^g   Galan, Pilar ^h   Bønaa, Kaare H ⁱ   Jamison, Rex ^j   Gaziano, J Michael ^k   Guarino, Peter ^l   Baron, John A ^m   Logan, Richard F A ⁿ   Giovannucci, Edward L ^o   Den Heijer, Martin ^p   Ueland, Per M ^a   Bennett, Derrick ^b   Collins, Rory ^b   Peto, Richard ^b   more..

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d MCMASTER UNIVERSITY   (Canada)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f ROYAL PERTH HOSPITAL   (Australia)

^g ROBARTS RESEARCH INSTITUTE   (Canada)

^h CNAM Université Paris 13 ^*  (France)

ⁱ UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k VA BOSTON HEALTHCARE SYSTEM   (United States)

^l VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^o HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; PLACEBO;

ARTICLE; CANCER INCIDENCE; COLORECTAL ADENOMA; DRUG EFFECT; HUMAN; LOG RANK TEST; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

EID: 84875382738     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62001-7     Document Type: Article

References (43)

1. Hibbard BM. The role of folic acid in pregnancy, with particular reference to anaemia, abruption and abortion. J Obstet Gynaecol Br Common W 1964; 71: 529-42.
2. Molloy AM, Kirke P, Hillary I, Weir DG, Scott JM. Maternal serum folate and vitamin B12 concentrations in pregnancies associated with neural tube defects. Arch Dis Child 1985; 80: 660-65.
3. Bower C, Stanley FJ. Dietary folate as a risk factor for neural tube defects: evidence from a case-control study in Western Australia. Med J Aust 1989; 150: 613-19.
4. Smithells RW, Sheppard S, Schorah CJ, et al. Possible prevention of neural tube defects by periconceptional vitamin supplementation. Lancet 1980; 1: 339-40.
5. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999; 341: 1485-90.
6. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-37.
7. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832-35.
8. Scientific Advisory Committee on Nutrition. Folate and disease prevention. London: The Stationery Office, 2006.
9. Centres for Disease Control and Prevention (CDC). Trends in wheat flour fortification with folic acid and iron worldwide, 2004 and 2007. MMWR Morb Mortal Wkly Rep 2008; 57: 8-10.
10. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340: 1449-54.
11. Sayed AR, Bourne D, Pattinson R, Nixon J, Henderson B. Decline in the prevalence of neural tube defects following folic acid fortification and its cost-benefit in South Africa. Birth Defects Res Clin Mol Teratol 2008; 82: 211-16.
12. López-Camelo JS, Castilla EE, Orioli IM; INAGEMP (Instituto Nacional deGenética Médica Populacional); CLAMC (Estudio Colaborativo Latino Americano de Malformaciones Congénitas). Folic acid flour fortification: impact on the frequencies of 52 congenital anomaly types in three South American countries. Am J Med Genet 2010; 152: 2444-58.
13. Australian Institute of Health and Welfare (AIHW). Mandatory folic acid and iodine fortification in Australia and New Zealand: baseline report for monitoring. Canberra: AIHW, 2011.
14. EFSA Meeting summary report. Folic acid: an update on scientific developments. European Food Safety Authority, 2010.
15. Scientific Advisory Committee on Nutrition. Folic acid and colorectal cancer risk: review of recommendations for folic acid mandatory fortification. London: Stationery Office, 2009.
16. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
17. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
18. Sanjoaquin MA, Allen NA, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 2005; 113: 825-38.
19. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006; 151: 282-87.
20. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Meta-analysis of 8 randomized trials involving 37485 individuals. Arch Intern Med 2010; 170: 1622-31.
21. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297: 2351-59.
22. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134: 29-38.
23. Wu K, Platz EA, Willett WC, et al. A randomized trial of folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr 2009; 90: 1623-31.
24. Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev 2007; 16: 1325-29.
25. Kim YI. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr 2004; 80: 1123-28.
26. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 2007; 109: 139-44.
27. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-70.
28. Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009; 302: 2119-26.
29. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
30. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B-vitamins and omega-3 fatty acids on cardiovascular diseases: a randomised placebo-controlled trial. BMJ 2010; 341: C6273 doi:10.1136.
31. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
32. VITATOPS Trial Study Group. B-vitamins in patients with recent transient ischaemic attack or stroke in the Vitamins To Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurology 2010; 9: 855-65.
33. Zhang SM, Cook NR, Albert CM, Gaziano JM, Buring JE, Manson JE. Effect of folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA 2008; 300: 2012-21.
34. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
35. Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010; 303: 2486-94.
36. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation 2002; 106 (suppl 2): 741S (abstr).
37. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction In Transplantation trial. Circulation 2011; 123: 1763-70.
38. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog in Cardiovasc Dis 1985; 27: 335-71.
39. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple end-point adjustment methods in clinical trials. Stat Med 1997; 16: 2529-42.
40. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359: 1357-66.
41. Baigent C, Peto R, Gray R, Parish S, Collins R. Large-scale randomized evidence: trials and meta-analyses of trials. In: Warrell D, Cox TM, Firth JD, eds. Oxford Textbook of Medicine, 5th edn. Oxford: Oxford University Press, 2011.
42. Wien TN, Pike E, Wisloff T, Staff A, Smeland S, Kemp M. Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open 2012; 2: e000653.
43. Figueiredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009: 101: 432-35.